Cargando…
Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model
Despite the routine use of porcine reproductive and respiratory syndrome (PRRS)-modified live vaccines, serious concerns are currently being raised due to their quick reversion to virulence and limited cross-protection against divergent PRRS virus (PRRSV) strains circulating in the field. Therefore,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617800/ https://www.ncbi.nlm.nih.gov/pubmed/34835189 http://dx.doi.org/10.3390/vaccines9111258 |
_version_ | 1784604593429151744 |
---|---|
author | Jeong, Chang-Gi Khatun, Amina Nazki, Salik Kim, Seung-Chai Noh, Yun-Hee Kang, Sang-Chul Lee, Dong-Uk Yang, Myeon-Sik Shabir, Nadeem Yoon, In-Joong Kim, Bumseok Kim, Won-Il |
author_facet | Jeong, Chang-Gi Khatun, Amina Nazki, Salik Kim, Seung-Chai Noh, Yun-Hee Kang, Sang-Chul Lee, Dong-Uk Yang, Myeon-Sik Shabir, Nadeem Yoon, In-Joong Kim, Bumseok Kim, Won-Il |
author_sort | Jeong, Chang-Gi |
collection | PubMed |
description | Despite the routine use of porcine reproductive and respiratory syndrome (PRRS)-modified live vaccines, serious concerns are currently being raised due to their quick reversion to virulence and limited cross-protection against divergent PRRS virus (PRRSV) strains circulating in the field. Therefore, a PRRS chimeric vaccine (JB1) was produced using a DNA-launched infectious clone by replacing open reading frames (ORFs) 3–6 with those from a mixture of two genetically different PRRSV2 strains (K07–2273 and K08–1054) and ORF1a with that from a mutation-resistant PRRSV strain (RVRp22) exhibiting an attenuated phenotype. To evaluate the safety and cross-protective efficacy of JB1 in a reproductive model, eight PRRS-negative pregnant sows were purchased and divided into four groups. Four sows in two of the groups were vaccinated with JB1, and the other 4 sows were untreated at gestational day 60. At gestational day 93, one vaccinated group and one nonvaccinated group each were challenged with either K07–2273 or K08–1054. All of the sows aborted or delivered until gestation day 115 (24 days post challenge), and the newborn piglets were observed up to the 28th day after birth, which was the end of the experiment. Overall, pregnant sows of the JB1-vaccinated groups showed no meaningful viremia after vaccination and significant reductions in viremia with K07–2273 and K08–1054, exhibiting significantly higher levels of serum virus-neutralizing antibodies than non-vaccinated sows. Moreover, the JB1-vaccinated groups did not exhibit any abortion due to vaccination and showed improved piglet viability and birth weight. The piglets from JB1-vaccinated sows displayed lower viral concentrations in serum and fewer lung lesions compared with those of the piglets from the nonvaccinated sows. Therefore, JB1 is a safe and effective vaccine candidate that confers simultaneous protection against two genetically different PRRSV strains. |
format | Online Article Text |
id | pubmed-8617800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86178002021-11-27 Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model Jeong, Chang-Gi Khatun, Amina Nazki, Salik Kim, Seung-Chai Noh, Yun-Hee Kang, Sang-Chul Lee, Dong-Uk Yang, Myeon-Sik Shabir, Nadeem Yoon, In-Joong Kim, Bumseok Kim, Won-Il Vaccines (Basel) Article Despite the routine use of porcine reproductive and respiratory syndrome (PRRS)-modified live vaccines, serious concerns are currently being raised due to their quick reversion to virulence and limited cross-protection against divergent PRRS virus (PRRSV) strains circulating in the field. Therefore, a PRRS chimeric vaccine (JB1) was produced using a DNA-launched infectious clone by replacing open reading frames (ORFs) 3–6 with those from a mixture of two genetically different PRRSV2 strains (K07–2273 and K08–1054) and ORF1a with that from a mutation-resistant PRRSV strain (RVRp22) exhibiting an attenuated phenotype. To evaluate the safety and cross-protective efficacy of JB1 in a reproductive model, eight PRRS-negative pregnant sows were purchased and divided into four groups. Four sows in two of the groups were vaccinated with JB1, and the other 4 sows were untreated at gestational day 60. At gestational day 93, one vaccinated group and one nonvaccinated group each were challenged with either K07–2273 or K08–1054. All of the sows aborted or delivered until gestation day 115 (24 days post challenge), and the newborn piglets were observed up to the 28th day after birth, which was the end of the experiment. Overall, pregnant sows of the JB1-vaccinated groups showed no meaningful viremia after vaccination and significant reductions in viremia with K07–2273 and K08–1054, exhibiting significantly higher levels of serum virus-neutralizing antibodies than non-vaccinated sows. Moreover, the JB1-vaccinated groups did not exhibit any abortion due to vaccination and showed improved piglet viability and birth weight. The piglets from JB1-vaccinated sows displayed lower viral concentrations in serum and fewer lung lesions compared with those of the piglets from the nonvaccinated sows. Therefore, JB1 is a safe and effective vaccine candidate that confers simultaneous protection against two genetically different PRRSV strains. MDPI 2021-10-31 /pmc/articles/PMC8617800/ /pubmed/34835189 http://dx.doi.org/10.3390/vaccines9111258 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jeong, Chang-Gi Khatun, Amina Nazki, Salik Kim, Seung-Chai Noh, Yun-Hee Kang, Sang-Chul Lee, Dong-Uk Yang, Myeon-Sik Shabir, Nadeem Yoon, In-Joong Kim, Bumseok Kim, Won-Il Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model |
title | Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model |
title_full | Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model |
title_fullStr | Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model |
title_full_unstemmed | Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model |
title_short | Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model |
title_sort | evaluation of the cross-protective efficacy of a chimeric prrsv vaccine against two genetically diverse prrsv2 field strains in a reproductive model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617800/ https://www.ncbi.nlm.nih.gov/pubmed/34835189 http://dx.doi.org/10.3390/vaccines9111258 |
work_keys_str_mv | AT jeongchanggi evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT khatunamina evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT nazkisalik evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT kimseungchai evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT nohyunhee evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT kangsangchul evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT leedonguk evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT yangmyeonsik evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT shabirnadeem evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT yooninjoong evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT kimbumseok evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel AT kimwonil evaluationofthecrossprotectiveefficacyofachimericprrsvvaccineagainsttwogeneticallydiverseprrsv2fieldstrainsinareproductivemodel |